Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios A Dimopoulos

Showing results (441-450 of 740) with videos related to

Pageof 74
Sort By:
Anticancer Research|November 27, 2008
Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic Cooperative Oncology GroupAngelos K Koutras, George Fountzilas, Urania Dafni, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 16, 2026
The prognostic value of red blood cell distribution width in AL amyloidosisDespina Fotiou, Erasmia Boutakoglou, Konstantinos Giannakas, et al.
Haematologica|June 21, 2011
CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myelomaEsperanza Such, José Cervera, Evangelos Terpos, et al.
Leukemia & Lymphoma|May 10, 2018
Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myelomaShaji Kumar, Brian Durie, Hareth Nahi, et al.
American Journal of Hematology|December 29, 2018
Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonatesEvangelos Terpos, Efstathios Kastritis, Ioannis Ntanasis-Stathopoulos, et al.
Blood|March 13, 2013
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosisAshutosh D Wechalekar, Stefan O Schonland, Efstathios Kastritis, et al.
Frontiers in Immunology|December 13, 2023
Rapid transient and longer-lasting innate cytokine changes associated with adaptive immunity after repeated SARS-CoV-2 BNT162b2 mRNA vaccinationsMargherita Rosati, Evangelos Terpos, Philip Homan, et al.
Vaccines|October 26, 2021
Nocebo-Prone Behavior Associated with SARS-CoV-2 Vaccine Hesitancy in Healthcare WorkersDimos D Mitsikostas, Konstantina Aravantinou-Fatorou, Christina Deligianni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate<sup>TM</sup> TrialJudith Trotman, Christian Buske, Alessandra Tedeschi, et al.
International Journal of Cardiology|June 18, 2022
Determining patterns of vascular function and structure in wild-type transthyretin cardiac amyloidosis. A comparative studyKimon Stamatelopoulos, Dimitrios Delialis, Georgios Georgiopoulos, et al.
Pageof 74

Showing results (441-450 of 740) with videos related to

Sort By:
Pageof 74
Anticancer Research|November 27, 2008
Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic Cooperative Oncology GroupAngelos K Koutras, George Fountzilas, Urania Dafni, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 16, 2026
The prognostic value of red blood cell distribution width in AL amyloidosisDespina Fotiou, Erasmia Boutakoglou, Konstantinos Giannakas, et al.
Haematologica|June 21, 2011
CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myelomaEsperanza Such, José Cervera, Evangelos Terpos, et al.
Leukemia & Lymphoma|May 10, 2018
Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myelomaShaji Kumar, Brian Durie, Hareth Nahi, et al.
American Journal of Hematology|December 29, 2018
Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonatesEvangelos Terpos, Efstathios Kastritis, Ioannis Ntanasis-Stathopoulos, et al.
Blood|March 13, 2013
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosisAshutosh D Wechalekar, Stefan O Schonland, Efstathios Kastritis, et al.
Frontiers in Immunology|December 13, 2023
Rapid transient and longer-lasting innate cytokine changes associated with adaptive immunity after repeated SARS-CoV-2 BNT162b2 mRNA vaccinationsMargherita Rosati, Evangelos Terpos, Philip Homan, et al.
Vaccines|October 26, 2021
Nocebo-Prone Behavior Associated with SARS-CoV-2 Vaccine Hesitancy in Healthcare WorkersDimos D Mitsikostas, Konstantina Aravantinou-Fatorou, Christina Deligianni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate<sup>TM</sup> TrialJudith Trotman, Christian Buske, Alessandra Tedeschi, et al.
International Journal of Cardiology|June 18, 2022
Determining patterns of vascular function and structure in wild-type transthyretin cardiac amyloidosis. A comparative studyKimon Stamatelopoulos, Dimitrios Delialis, Georgios Georgiopoulos, et al.
Pageof 74